AxoGen Seeks Accelerated FDA Review for Avance Nerve Graft®
Company Announcements

AxoGen Seeks Accelerated FDA Review for Avance Nerve Graft®

AxoGen ( (AXGN) ) just unveiled an update.

Axogen Inc., a leader in nerve repair solutions, has announced the completion of its BLA submission to the FDA for the Avance Nerve Graft®. This milestone reflects the company’s commitment to enhancing the quality of life for patients with peripheral nerve damage. With a request for priority review, Axogen could see a reduced FDA review timeline, potentially accelerating the availability of this innovative therapy to those in need. This submission underscores Axogen’s dedication to advancing the field of regenerative medicine and its comprehensive portfolio of nerve repair products.

For an in-depth examination of AXGN stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskAxogen Reports Strong Q3 Growth and FDA Progress
TheFlyRaymond James says AxoGen selloff ‘overdone,’ raises price target to $18
TheFlyAxoGen trading resumes
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App